m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02502)
Name
LDC1267
Synonyms
LDC1267; 1361030-48-9; LDC-1267; CHEMBL3808844; SCHEMBL167963; GTPL8247; MolPort-035-944-330; EX-A2265; AOB87188; BCP14023; BDBM50172075; s7638; ZINC113241878; AKOS026750422; CS-3603; SB19391; NCGC00386431-02; HY-12494; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-2-methylphenyl)-1H-pyrazole-3-carboxamide
    Click to Show/Hide
Status
Investigative
Structure
Formula
C30H26F2N4O5
InChI
1S/C30H26F2N4O5/c1-5-40-28-16-36(23-8-6-18(31)12-17(23)2)35-29(28)30(37)34-19-7-9-25(21(32)13-19)41-24-10-11-33-22-15-27(39-4)26(38-3)14-20(22)24/h6-16H,5H2,1-4H3,(H,34,37)
InChIKey
ISPBCAXOSOLFME-UHFFFAOYSA-N
PubChem CID
56847486
TTD Drug ID
D09TFN
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Tyrosine-protein kinase Mer (MERTK)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for LDC1267. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of LDC1267 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tyrosine-protein kinase Mer (MERTK) is a therapeutic target for LDC1267. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of LDC1267 through regulating the expression of Tyrosine-protein kinase Mer (MERTK). [1], [2]
Tyrosine-protein kinase UFO (AXL)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tyrosine-protein kinase UFO (AXL) is a therapeutic target for LDC1267. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of LDC1267 through regulating the expression of Tyrosine-protein kinase UFO (AXL). [3], [4]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tyrosine-protein kinase UFO (AXL) is a therapeutic target for LDC1267. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of LDC1267 through regulating the expression of Tyrosine-protein kinase UFO (AXL). [4], [5]
References
Ref 1 A dynamic N(6)-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018 Nov;28(11):1062-1076. doi: 10.1038/s41422-018-0097-4. Epub 2018 Oct 8.
Ref 2 G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19. doi: 10.1182/blood-2013-04-493916. Epub 2014 Feb 14.
Ref 3 METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol. 2018 Nov;151(2):356-365. doi: 10.1016/j.ygyno.2018.09.015. Epub 2018 Sep 21.
Ref 4 AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153. doi: 10.1186/s12943-019-1090-3.
Ref 5 Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis. Cell Stem Cell. 2020 Jul 2;27(1):81-97.e8. doi: 10.1016/j.stem.2020.04.001. Epub 2020 May 12.